GHK-Cu vs TB-500
Reviewed by the BestHealingPeptides Editorial Team ·
GHK-Cu and TB-500 are sometimes grouped together as 'tissue-repair peptides', but the two operate at very different scales — GHK-Cu primarily as a transcriptional modulator of dermal fibroblasts, TB-500 primarily as a cell-migration peptide.
GHK-Cu
A naturally occurring copper-binding tripeptide (Gly-His-Lys) complexed with Cu(II). Extensively studied in dermatology for wound healing, collagen synthesis, antioxidant defence, and hair-follicle stimulation.
TB-500
A synthetic peptide commonly described as a fragment of thymosin beta-4 incorporating the actin-binding 'LKKTETQ' motif. Studied for soft-tissue repair, wound healing, and cardiac tissue regeneration in animal models.
| Aspect | GHK-Cu | TB-500 |
|---|---|---|
| Lead mechanism | Cu(II) delivery → fibroblast transcriptional programme (collagen, elastin, antioxidant genes) | Actin sequestration → directed cell migration |
| Standard route | Topical (cosmetic + research) | Injectable (lyophilised, BAC water) |
| Typical concentrations | 1–10 nM in vitro; 0.05–0.5% topical | Reconstituted to research-specified concentration |
| Dermal evidence | Substantial — gene-expression and topical wound studies | Mostly extrapolated from full-length Tβ4 |
| UK regulatory | Legal cosmetic ingredient; not licensed as medicine | Not licensed; WADA S2 |
| Key formulation gotcha | Avoid co-formulation with reducing agents (vitamin C disrupts Cu²⁺) | Plastic adsorption; use low-binding labware |
Mechanism
GHK-Cu (glycyl-L-histidyl-L-lysine complexed with Cu²⁺) acts as a copper-delivery vehicle to two key cuproenzymes — lysyl oxidase (which cross-links collagen and elastin fibres) and superoxide dismutase (the principal intracellular antioxidant). It is additionally a broad transcriptional modulator, with Pickart's genome-wide microarray data demonstrating >4,000 genes regulated more than 50% in human dermal fibroblasts on exposure. Balanced upregulation of MMP-2/-9 alongside their inhibitors TIMP-1/-2 supports coordinated matrix remodelling rather than uncontrolled proteolysis, and TGF-β1 pathway suppression restrains myofibroblast differentiation. TB-500 operates through the mechanistically distinct route of G-actin sequestration via its LKKTETQ heptapeptide motif, driving directed cell migration through lamellipodia formation with parallel VEGF upregulation.
Dermal evidence
GHK-Cu has by far the larger dermatological evidence base, dating from Pickart's 1973 discovery through five decades of cosmetic-dermatology research, topical wound-healing studies, gene-expression analyses in cultured human dermal fibroblasts, and small-animal wound-closure models. Diabetic wound-healing studies (streptozotocin rat models) have shown accelerated closure with topical GHK-Cu hydrogels and increased hydroxyproline (a collagen content marker) in healed tissue. TB-500's dermal evidence is mostly extrapolated from full-length thymosin beta-4 work — Malinda's murine excisional wound data (~40% faster closure vs vehicle) is the most-cited reference — but relatively little dedicated research uses the LKKTETQ fragment specifically in dermal models. Full-length Tβ4's paracrine and autocrine dermal effects, particularly via laminin-5 upregulation on keratinocytes, are better characterised than the fragment's.
Formulation and route
GHK-Cu is commonly used topically in research and cosmetic formulations (typically 0.05-0.5% in topical preparations; nanomolar-to-micromolar concentrations in vitro). Topical delivery bypasses the systemic absorption limitations of hydrophilic peptides. Critical formulation considerations include avoiding reducing agents (vitamin C, sulfites) that disrupt the Cu²⁺ complex, avoiding EDTA which chelates the copper, and maintaining pH within 5-8 for complex stability. TB-500 is typically used as an injectable lyophilised peptide reconstituted with bacteriostatic water, delivered subcutaneously in research protocols. As a cationic peptide with substantial arginine content, it exhibits meaningful adsorption to standard polystyrene labware — low-binding vessels and BSA supplementation (0.01-0.1%) mitigate nominal-vs-effective concentration mismatch in cell-culture work.
Regulatory
GHK-Cu is widely used as a legal cosmetic ingredient in the UK under the Cosmetic Products Regulation, INCI-listed as Copper Tripeptide-1 — no MHRA authorisation is required for cosmetic use, and consumer products with GHK-Cu at 0.05-0.5% are freely available. It is not on the WADA Prohibited List. Neither peptide is licensed as a medicine in the UK. TB-500 sits under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a thymosin beta-4 derivative, with both in-competition and out-of-competition prohibition for athletes. Anti-doping enforcement of TB-500 has advanced with targeted LC-MS/MS detection methods.
Choosing between them
For dermal collagen synthesis, wound closure, and anti-ageing skin research, GHK-Cu is the deeper-evidence choice with substantial cosmetic-dermatology literature and a legal UK cosmetic-ingredient regulatory pathway. Its multi-mechanism pharmacology (copper delivery, transcriptional modulation, anti-fibrotic effects) is well-characterised. TB-500 is better suited to injectable soft-tissue repair research — particularly tendon, cardiac, and corneal models where its cell-migration mechanism is most mechanistically apt — rather than dermal contexts. The two are not typically combined in the same formulation given the copper reactivity considerations of GHK-Cu.
Verdict
For dermal research, GHK-Cu has the stronger and longer-standing evidence base and the practical advantage of legal UK cosmetic-ingredient status. TB-500 remains relevant to research on injectable soft-tissue repair — tendon, cardiac, corneal — where its actin-binding cell-migration mechanism is most plausible, but is not the appropriate choice for dermal or topical research where GHK-Cu's dermal-fibroblast pharmacology is far better characterised.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.